Immune adjuvants in early life: Targeting the innate immune system to overcome impaired adaptive response

Immunotherapy

Volumn 1, Issue 5, 2009, Pages 883-895

  De Brito, Cyro Alves ^a   Goldoni, Adriana Letícia ^a   Notomi Sato, Maria ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adjuvant; Children; Immunomodulation; Innate immunity; Neonate; Toll like receptor

Indexed keywords

IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT;

ADAPTIVE IMMUNITY; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TH2 CELL;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; CELL COMMUNICATION; CELL DIFFERENTIATION; DENDRITIC CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INFANT, NEWBORN; TH1-TH2 BALANCE; TOLL-LIKE RECEPTORS;

EID: 77953437777     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.38     Document Type: Review

References (134)

1. Siegrist CA: Mechanisms underlying adverse reactions to vaccines. J. Comp. Pathol. 137 (Suppl. 1), S46-S50 (2007).
2. Levy O: Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat. Rev. Immunol. 7, 379-390 (2007).
3. Rigato PO, Fusaro AE, Victor JR, Sato MN: Maternal immunization to modulate the development of allergic response and pathogen infections. Immunotherapy 1, 141-156 (2009).
4. Kovarik J, Siegrist CA: Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators. Immunol. Cell. Biol. 76, 222-236 (1998).
5. Adkins B: T-cell function in newborn mice and humans. Immunol. Today 20, 330-335 (1999).
6. Veerman AJ, van Ewijk W: White pulp compartments in the spleen of rats and mice. A light and electron microscopic study of lymphoid and non-lymphoid celltypes in T- and B-areas. Cell Tissue Res. 156, 417-441 (1975).
7. Dijkstra CD, Dopp EA: Ontogenetic development of T- and B-lymphocytes and non-lymphoid cells in the white pulp of the rat spleen. Cell Tissue Res. 229, 351-363 (1983).
8. Marshall-Clarke S, Tasker L, Parkhouse RM: Immature B lymphocytes from adult bone marrow exhibit a selective defect in induced hyperexpression of major histocompatibility complex class II and fail to show B7.2 induction. Immunology 100, 141-151 (2000). (Pubitemid 30348859)
9. Dadaglio G, Sun CM, Lo-Man R, Siegrist CA, Leclerc C: Efficient in vivo priming of specific cytotoxic T cell responses by neonatal dendritic cells. J. Immunol. 168, 2219-2224 (2002). (Pubitemid 34171821)
10. Langrish CL, Buddle JC, Thrasher AJ, Goldblatt D: Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin. Exp. Immunol. 128, 118-123 (2002).
11. Bot A, Bona C: Genetic immunization of neonates. Microbes Infect. 4, 511-520 (2002).
12. Adkins B, Leclerc C, Marshall-Clarke S: Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4, 553-564 (2004).
13. Pihlgren M, Schallert N, Tougne C et al.: Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur. J. Immunol. 31, 939-946 (2001).
14. Siegrist CA: The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol. 137(Suppl. 1), S4-S9 (2007).
15. The WHO young infants study group: Conclusions from the WHO multicenter study of serious infections in young infants. Pediatr. Infect. Dis. J. 18, S32-S34 (1999).
16. Kanswal S, Katsenelson N, Selvapandiyan A, Bram RJ, Akkoyunlu M: Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL. J. Immunol. 15, 976-990 (2008).
17. Yan M, Wang H, Chan B et al.: Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2, 638-643 (2001).
18. von Bülow GU, van Deursen JM, Bram RJ: Regulation of the T-independent humoral response by TACI. Immunity 14, 573-582 (2001).
19. Pihlgren M, Friedli M, Tougne C et al.: Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J. Immunol. 176, 165-172 (2006). (Pubitemid 43023260)
20. Schallert N, Pihlgren M, Kovarik J et al.: Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines. Eur. J. Immunol. 32, 752-760 (2002).
21. Kovarik J, Gaillard M, Martinez X et al.: Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector. Virology 285,12-20 (2001).
22. Siegrist CA: Neonatal and early life vaccinology. Vaccine 19, 3331-3346 (2001).
23. Adkins B, Williamson T, Guevara P, Bu Y: Murine neonatal lymphocytes show rapid early cell cycle entry and cell division. J. Immunol. 170, 4548-4556 (2003). (Pubitemid 36519960)
24. Morein B, Abusugra I, Blomqvist G: Immunity in neonates. Vet. Immunol. Immunopathol. 87, 207-213 (2002).
25. Morein B, Blomqvist G, Hu K: Immune responsiveness in the neonatal period. J. Comp. Pathol. 137(Suppl. 1), S27-S31 (2007).
26. Wegmann TG, Lin H, Guilbert L, Mosmann TR: Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol. Today. 14, 353-356 (1993).
27. Mitchell MD, Trautman MS, Dudley DJ: Cytokine networking in the placenta. Placenta 14, 249-275 (1993).
28. Chaouat G, Zourbas S, Ostojic S et al.: A brief review of recent data on some cytokine expressions at the materno-foetal interface which might challenge the classical Th1/Th2 dichotomy. J. Reprod. Immunol. 53, 241-256 (2002).
29. Anne Croy B, van den Heuvel MJ, Borzychowski AM, Tayade C: Uterine natural killer cells: a specialized differentiation regulated by ovarian hormones. Immunol. Rev. 214, 161-185 (2006).
30. Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA: Partial correction of the Th2/Th1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Eur. J. Immunol. 26, 2666-2670 (1996).
31. Lee SM, Suen Y, Chang L et al.: Decreased interleukin-12 (IL-12) from activated cord versus adult peripheral blood mononuclear cells and upregulation of interferon-γ, natural killer, and lymphokine-activated killer activity by IL-12 in cord blood mononuclear cells. Blood 88, 945-954 (1996). (Pubitemid 26333318)
32. Adkins B, Bu Y, Guevara P: The generation of Th memory in neonates versus adults: prolonged primary Th2 effector function and impaired development of Th1 memory effector function in murine neonates. J. Immunol. 166, 918-925 (2001). (Pubitemid 32060246)
33. Bot A, Antohi S, Bot S, Garcia-Sastre A, Bona C: Induction of humoral and cellular immunity against influenza virus by immunization of newborn mice with a plasmid bearing a hemagglutinin gene. Int. Immunol. 9, 1641-1650 (1997).
34. Adkins B, Du RQ: Newborn mice develop balanced Th1/Th2 primary effector responses in vivo but are biased to Th2 secondary responses. J. Immunol. 160, 4217-4224 (1998). ■■ Demonstrates that while neonatal and adult primary cytokine profiles are very similar, Th2 secondary responses predominate in animals first immunized as newborns. (Pubitemid 28217275)
35. + cells are poised for rapid Th2 effector-like function. J. Immunol. 178, 2667-2678 (2007). (Pubitemid 46333143)
36. Li L, Lee HH, Bell JJ et al.: IL-4 utilizes an alternative receptor to drive apoptosis of Th1 cells and skews neonatal immunity toward Th2. Immunity 20, 429-440 (2004). (Pubitemid 38482121)
37. Adkins B: Heterogeneity in the CD4 T cell compartment and the variability of neonatal immune responsiveness. Curr. Immunol. Rev. 3, 151-159 (2007).
38. Lee HH, Hoeman CM, Hardaway JC et al.: Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. J. Exp. Med. 205, 2269-2280 (2008).
39. Andersson AC, Seppälä U, Rudin A: Activation of human neonatal monocyte-derived dendritic cells by lipopolysaccharide down-regulates birch allergen-induced Th2 differentiation. Eur. J. Immunol. 34, 3516-3524 (2004).
40. Fadel SA, Ozaki DA, Sarzotti M: Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates. J. Immunol. 169, 3293-3300 (2002).
41. + memory cells rival adult-primed memory cells in antigen-driven expansion and anti-viral protection. Int. Immunol. 18, 249-257 (2006).
42. + T cell responses to herpes simplex virus type 2 in neonatal mice. J. Immunol. 180, 1556-1564 (2008).
43. + regulatory T cells on the immune response to rotavirus infection. Vaccine 26, 5601-5611 (2008).
44. Sakaguchi S, Sakaguchi N: Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int. Rev. Immunol. 24, 211-226 (2005).
45. + natural regulatory T cells are specific for microbial antigens. J. Exp. Med. 203, 777-788 (2006). ■ Antigen-specific natural regulatory T cells (Tregs) are restricted to sites of infection and their survival is strictly dependent on antigen persistence.
46. + cells induced in utero as a consequence of placental Plasmodium falciparum infection. J. Infect. Dis. 193, 146-154 (2006).
47. Legrand FA, Nixon DF, Loo CP et al.: Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. PLoS ONE 1, e102 (2006).
48. Nilsson J, Boasso A, Velilla PA et al.: HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 108, 3808-3817 (2006). (Pubitemid 44864563)
49. Adkins B: Neonatal T cell function. J. Pediatr. Gastroenterol. Nutr. 40(Suppl. 1), S5-S7 (2005).
50. Sarzotti M, Robbins DS, Hoffman PM: Induction of protective CTL responses in newborn mice by a murine retrovirus. Science 271, 1726-1728 (1996). (Pubitemid 26102820)
51. Martinez X, Brandt C, Saddallah F et al.: DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life. Proc. Natl Acad. Sci. USA 94, 8726-8731 (1997).
52. Stambas J, Pietersz G, McKenzie I, Nagabhushanam V, Cheers C: Oxidised mannan-listeriolysin O conjugates induce Th1/Th2 cytokine responses after intranasal immunisation. Vaccine 20, 1877-1886 (2002).
53. Goriely S, Goldman M: From tolerance to autoimmunity: is there a risk in early life vaccination? J. Comp. Pathol. 137(Suppl. 1), S57-S61 (2007).
54. Bowie AG, Haga IR: The role of Toll-like receptors in the host response to viruses. Mol. Immunol. 42, 859-867 (2005).
55. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu. Rev. Immunol. 21, 335-376 (2003).
56. Lauw FN, Caffrey DR, Golenbock DT: Of mice and man: TLR11 (finally) finds profilin. Trends Immunol. 26, 509-511 (2005).
57. Akira S, Takeda K: Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499-511 (2004).
58. Reis e Sousa C: Toll-like receptors and dendritic cells: for whom the bug tolls. Semin. Immunol. 16, 27-34 (2004).
59. Pasare C, Medzhitov R: Toll-like receptors and acquired immunity. Semin. Immunol. 16, 23-26 (2004).
60. Tovey MG, Lallemand C, Thyprhonitis G: Adjuvant activity of type I interferons. Biol. Chem. 389, 541-545 (2008).
61. Gearing AJ: Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol. Cell. Biol. 85, 490-494 (2007). ■ Reviews the commercial approaches being undertaken to develop new Toll-like receptor (TLR) drugs.
62. Vollmer J, Weeratna R, Payette P et al.: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34, 251-262 (2004).
63. Ghosh TK, Mickelson DJ, Fink J et al: Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. Comparison with T cell receptor-induced responses. Cell. Immunol. 243, 48-57 (2006).
64. Martin TR, Ruzinski JT, Wilson CB, Skerrett SJ: Effects of endotoxin in the lungs of neonatal rats: age-dependent impairment of the inflammatory response. J. Infect. Dis. 171, 134-144 (1995).
65. De Wit D, Tonon S, Olislagers V et al.: Impaired responses to toll-like receptor 4 and toll-like receptor 3 ligands in human cord blood. J. Autoimmun. 21, 277-281 (2003). (Pubitemid 37410116)
66. Levy O, Zarember KA, Roy RM et al.: Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-α induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. J. Immunol. 173, 4627-4634 (2004). ■■ Neonatal plasma reduces monocyte responses to multiple TLR ligands, but not to R-848. (Pubitemid 39280696)
67. Levy O, Suter EE, Miller RL, Wessels MR: Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. Blood 108, 1284-1290 (2006). (Pubitemid 44232026)
68. Zhao J, Kim KD, Yang X, Auh S, Fu YX, Tang H: Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc. Natl Acad. Sci. USA. 105, 7528-7533 (2008).
69. Pedras-Vasconcelos JA, Goucher D, Puig M et al.: CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus. J. Immunol. 176, 4940-4949 (2006).
70. Barrier M, Lacroix-Lamandé S, Mancassola R et al.: Oral and intraperitoneal administration of phosphorothioate oligodeoxynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice. J. Infect. Dis. 2006 193, 1400-1407 (2006).
71. Huang CF, Wu TC, Chu YH et al.: Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice. Scand. J. Immunol. 68, 502-510 (2008).
72. Kline JN, Waldschmidt TJ, Businga TR et al.: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160, 2555-2559 (1998).
73. Tulic MK, Fiset PO, Christodoulopoulos P et al.: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113, 235-241 (2004).
74. Brito CA, Fusaro AE, Victor JR et al.: CpG induces Th1 response in neonatal mice but does not suppress anaphylactic IgG1 response: possible role of low TLR-9 expression. Clin. Immunol. 123, S78-S79 (2007).
75. + B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. Immunity 22, 467-477 (2005).
76. Zhang X, Deriaud E, Jiao X, Braun D, Leclerc C, Lo-Man R: Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J. Exp. Med. 204, 1107-1118 (2007).
77. Berland R, Wortis HH: Origins and functions of B-1 cells with notes on the role of CD5. Annu. Rev. Immunol. 20, 253-300 (2002).
78. Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL: CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol. Med. Microbiol 32, 65-71 (2001).
79. Hemmi H, Kaisho T, Takeuchi O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3, 196-200 (2002).
80. Hesling C, D'Incan M, Mansard S et al.: In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br. J. Dermatol. 150, 761-767 (2004).
81. Myhre PE, Levy ML, Eichenfield LF et al.: Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Pediatr. Dermatol. 25, 88-95 (2008).
82. Fallah H, Fischer G, Zagarella S: Pyogenic granuloma in children: treatment with topical imiquimod. Australas. J. Dermatol. 48, 217-220 (2007).
83. Wagstaff AJ, Perry CM: Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 67, 2187-2210 (2007).
84. Schaen L, Mercurio MG: Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream. Pediatr. Dermatol. 18, 450-452 (2001).
85. Barry RB, Hughes BR, Cook LJ: Involution of infantile haemangiomas after imiquimod 5% cream. Clin. Exp. Dermatol. 33, 446-449 (2008).
86. McKenzie IF, Apostolopoulos V, Lees C et al.: Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. Vet. Immunol. Immunopathol. 63, 185-190 (1998).
87. Cox E, Verdonck F, Vanrompay D, Goddeeris B: Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res. 37, 511-539 (2006).
88. Tang CK, Sheng KC, Esparon SE et al.: Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials 30, 1389-1400 (2009).
89. Sheng KC, Pouniotis DS, Wright MD et al.: Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells. Immunology 118, 372-383 (2006).
90. Karanikas V, Hwang LA, Pearson J et al.: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest. 100, 2783-2792 (1997).
91. Stambas J, Pietersz G, McKenzie I, Cheers C: Oxidised mannan as a novel adjuvant inducing mucosal IgA production. Vaccine 20, 1068-1078 (2002). (Pubitemid 34135942)
92. Gelman AE, Zhang J, Choi Y, Turka LA: Toll-like receptor ligands directly promote activated CD4+ T cell survival. J. Immunol. 172, 6065-6073 (2004). (Pubitemid 38621208)
93. + T cells. Immunol. Letters 108, 183-188 (2007).
94. + T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 182, 55-62 (2009). ■ TLR agonists may directly increase cytotoxic T-lymphocyte activity in newborns.
95. van Maren WW, Jacobs J F, de Vries IJ, Nierkens S, Adema GJ: Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology 124, 445-452 (2008).
96. + T cell effector function in a murine model of inflammatory bowel disease. J. Immunol. 180, 1886-1894 (2008).
97. Fischer M, Ehlers M: Toll-like receptors in autoimmunity. Ann. NY Acad. Sci. 1143, 21-34 (2008).
98. Fearon DT, Austen KF: Current concepts in immunology: the alternative pathway of complement - a system for host resistance to microbial infection. N. Engl. J. Med. 303, 259-263 (1980).
99. Test ST, Mitsuyoshi J, Connolly CC, Lucas AH: Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect. Immun. 69, 3031-3040 (2001).
100. Toapanta FR, Ross TM: Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol. Res. 36, 197-210 (2006).
101. Griffioen AW, Toebes EA, Zegers BJ, Rijkers GT: Role of CR2 in the human adult and neonatal in vitro antibody response to type 4 pneumococcal polysaccharide. Cell. Immunol. 143, 11-22 (1992).
102. Mond JJ, Lees A, Snapper CM: T cell-independent antigens type 2. Annu. Rev. Immunol. 13, 655-692 (1995).
103. Gray BM, Dillon HC Jr: Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr. Infect. Dis. 5, 201-207 (1986).
104. Musher DM: Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 14, 801-807 (1992).
105. Douglas RM, Paton JC, Duncan SJ, Hansman DJ: Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 148, 131-137 (1983).
106. Dagan R, Muallem M, Melamed R, Leroy O, Yagupsky P: Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr. Infect. Dis. J. 16, 1060-1064 (1997).
107. Sigurdardottir ST, Ingolfsdottir G, Davidsdottir K et al.: Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine. Pediatr. Infect. Dis. J. 21, 548-554 (2002).
108. Ahman H, Kayhty H, Lehtonen H et al.: Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr. Infect. Dis. J. 17, 211-216 (1998).
109. Suradhat S, Braun RP, Lewis PJ, et al.: Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet. Immunol. Immunopathol. 83, 79-92 (2001).
110. Bergmann-Leitner ES, Scheiblhofer S, Weiss R et al.: C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. Int. Immunol. 17, 245-255 (2005).
111. Gor DO, Ding X, Li Q, Greenspan NS: Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. Immunol. Lett. 102, 38-49 (2006).
112. Bendelac A, Rivera MN, Park SH, Roark JH: Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu. Rev. Immunol.15, 535-562 (1997).
113. + NKT lymphocytes are activated memory cells. Eur. J. Immunol. 30, 1544-1550 (2000).
114. van Der Vliet HJ, Nishi N, de Gruijl TD et al.: Human natural killer T cells acquire a memory-activated phenotype before birth. Blood 95, 2440-2442 (2000). (Pubitemid 30167748)
115. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV: Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J. Exp. Med. 192, 921-930 (2000).
116. Kadowaki N, Antonenko S, Ho S et al.: Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J. Exp. Med. 193, 1221-1226 (2001).
117. Motohashi S, Nagato K, Kunii N et al.: A Phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small-cell lung cancer. J. Immunol. 182, 2492-2501 (2009).
118. Eger KA, Sundrud MS, Motsinger AA et al.: Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions. PLoS ONE 1, E50 (2006).
119. + natural killer T cells of healthy volunteers and cancer patients using α-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res. 63, 4101-4106 (2003). (Pubitemid 36917933)
120. Matsuda JL, Gapin L, Baron JL et al.: Mouse Vα 14i natural killer T cells are resistant to cytokine polarization in vivo. Proc. Natl Acad. Sci. USA 100, 8395-8400 (2003).
121. + thymocytes selected by MHC class I molecules. Science 263, 1774-1778 (1994). (Pubitemid 24131588)
122. + cells in the liver of mice. J. Exp. Med. 180, 699-704 (1994).
123. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M et al.: α -galactosylceramide-activated Vα 14 natural killer T cells mediate protection against murine malaria. Proc. Natl Acad. Sci. USA 97, 8461-8466 (2000).
124. Strachan DP: Hay fever, hygiene, and household size. BMJ 299, 1259-1260 (1989). ■ First to suggest that reduced family size, improvement in household amenities and personal cleanliness could be related to the increasing incidence of allergic disorders.
125. Shirakawa T, Enomoto T, Shimazu S, Hopkin JM: The inverse association between tuberculin responses and atopic disorder. Science 275, 77-79 (1997). (Pubitemid 27020311)
126. Erb KJ, Holloway JW, Sobeck A, Moll H, Le Gros G: Infection of mice with Mycobacterium bovis-bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. J. Exp. Med. 187, 561-569 (1998).
127. Aaby P, Shaheen SO, Heyes CB et al.: Early BCG vaccination and reduction in atopy in Guinea-Bissau. Clin. Exp. Allergy 30, 644-650 (2000).
128. Obihara CC, Beyers N, Gie RP et al.: Inverse association between Mycobacterium tuberculosis infection and atopic rhinitis in children. Allergy 60, 1121-1125 (2005).
129. Obihara CC, Kimpen JL, Gie RP et al.: Mycobacterium tuberculosis infection may protect against allergy in a tuberculosis endemic area. Clin. Exp. Allergy 36, 70-76 (2006).
130. Linehan MF, Frank TL, Hazell ML et al.: Is the prevalence of wheeze in children altered by neonatal BCG vaccination? J. Allergy Clin. Immunol. 119, 1079-1085 (2007).
131. Yazdanbakhsh M, Kremsner PG, van Ree R: Allergy, parasites, and the hygiene hypothesis. Science 296, 490-494 (2002).
132. Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911-920 (2002).
133. Zuany-Amorim C, Sawicka E, Manlius C et al.: Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. 8, 625-629 (2002).
134. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J: Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J. Exp. Med. 197, 403-411 (2003).